View Item 

Show simple item record

Challenges facing pathologists evaluating PD‐L1 in head & neck squamous cell carcinoma
dc.contributor.authorGirolami, Ilaria
dc.contributor.authorPantanowitz, Liron
dc.contributor.authorBarberis, Massimo
dc.contributor.authorPaolino, Gaetano
dc.contributor.authorBrunelli, Matteo
dc.contributor.authorVigliar, Elena
dc.contributor.authorMunari, Enrico
dc.contributor.authorSatturwar, Swati
dc.contributor.authorTroncone, Giancarlo
dc.contributor.authorEccher, Albino
dc.date.accessioned2021-11-02T00:47:20Z
dc.date.available2022-11-01 20:47:19en
dc.date.available2021-11-02T00:47:20Z
dc.date.issued2021-10
dc.identifier.citationGirolami, Ilaria; Pantanowitz, Liron; Barberis, Massimo; Paolino, Gaetano; Brunelli, Matteo; Vigliar, Elena; Munari, Enrico; Satturwar, Swati; Troncone, Giancarlo; Eccher, Albino (2021). "Challenges facing pathologists evaluating PD‐L1 in head & neck squamous cell carcinoma." Journal of Oral Pathology & Medicine (9): 864-873.
dc.identifier.issn0904-2512
dc.identifier.issn1600-0714
dc.identifier.urihttps://hdl.handle.net/2027.42/170876
dc.description.abstractBackgroundProgrammed death‐ligand 1 (PD‐L1) expression with combined positive score (CPS) ≥1 is required for administration of checkpoint inhibitor therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The 22C3 pharmDx Dako immunohistochemical assay is the one approved as companion diagnostic for pembrolizumab, but many laboratories work on other platforms and/or with other clones, and studies exploring the potential interchangeability of assays have appeared.Evidence from the literatureAfter review of the literature, it emerges that the concordance among assays ranges from fair to moderate, with a tendence of assay SP263 to yield a higher quota of positivity and of assay SP142 to stain better immune cells. Moreover, pathologists achieve very good concordance in assessing PD‐L1 CPS, particularly with SP263.ConclusionsDifferences in terms of platforms, procedures, and study design still preclude a quantitative synthesis of evidence and clearly further work is needed to draw stronger conclusions on the interchangeability of PD‐L1 assays in HNSCC.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherprogrammed death‐ligand 1
dc.subject.otherreview
dc.subject.otherhead and neck squamous cell carcinoma
dc.subject.otherimmunohistochemical assay
dc.subject.othercombined positive score
dc.titleChallenges facing pathologists evaluating PD‐L1 in head & neck squamous cell carcinoma
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170876/1/jop13220_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170876/2/jop13220.pdf
dc.identifier.doi10.1111/jop.13220
dc.identifier.sourceJournal of Oral Pathology & Medicine
dc.identifier.citedreferenceHirsch FR, McElhinny A, Stanforth D, et al. PD‐L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD‐L1 IHC assay comparison project. J Thorac Oncol. 2017; 12: 208 ‐ 222. https://doi.org/10.1016/j.jtho.2016.11.2228
dc.identifier.citedreferenceCramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: recent advances and future directions. Oral Oncol. 2019; 99: 104460 ‐ https://doi.org/10.1016/j.oraloncology.2019.104460
dc.identifier.citedreferenceEmancipator K, Huang L, Aurora‐Garg D, et al. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2021; 34: 532 ‐ 541. https://doi.org/10.1038/s41379‐020‐00710‐9
dc.identifier.citedreferenceConcha‐Benavente F, Srivastava RM, Trivedi S, et al. Identification of the cell‐intrinsic and ‐extrinsic pathways downstream of EGFR and IFNγ that induce PD‐L1 expression in head and neck cancer. Cancer Res. 2016; 76: 1031 ‐ 1043. https://doi.org/10.1158/0008‐5472.CAN‐15‐2001
dc.identifier.citedreferenceAncevski Hunter K, Socinski MA, Villaruz LC. PD‐L1 testing in guiding patient selection for pd‐1/pd‐l1 inhibitor therapy in lung cancer. Mol Diagn Ther. 2018; 22: 1 ‐ 10. https://doi.org/10.1007/s40291‐017‐0308‐6
dc.identifier.citedreferenceFood and Drug Administration. PD‐L1 IHC 22C3 pharmDx interpretation manual – Head and Neck Squamous Cell Carcinoma (HNSCC). https://www.agilent.com/cs/library/usermanuals/public/29314_22c3_pharmDx_hnscc_interpretation_manual_us.pdf. Accessed March 24, 2021.
dc.identifier.citedreferenceFood and Drug Administration. PD‐L1 IHC 28‐8 pharmDx interpretation manual – Head and Neck Squamous Cell Carcinoma (HNSCC). https://www.agilent.com/cs/library/usermanuals/public/29186_pd‐l1‐ihc‐28‐8‐interpretation‐manual‐scchn.pdf. Accessed March 24, 2021.
dc.identifier.citedreferenceIonescu DN, Downes MR, Christofides A, Tsao MS. Harmonization of PD‐L1 testing in oncology: a Canadian pathology perspective. Curr Oncol. 2018; 25: e209 ‐ e216. https://doi.org/10.3747/co.25.4031
dc.identifier.citedreferencede Ruiter EJ, Mulder FJ, Koomen BM,, et al. Comparison of three PD‐L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021; 34: 1125 ‐ 1132. https://doi.org/10.1038/s41379‐020‐0644‐7
dc.identifier.citedreferenceCrosta S, Boldorini R, Bono F, et al. PD‐L1 testing and squamous cell carcinoma of the head and neck: a multicenter study on the diagnostic reproducibility of different protocols. Cancers (Basel). 2021; 13: 292. https://doi.org/10.3390/cancers13020292
dc.identifier.citedreferenceRamos M, Baldion A, Suarez D, et al. Immunohistochemistry analysis of PD‐L1 expression in head and neck cancer. Virchows Arch. 2019; 475 ( S1 ): 1 ‐ 436. https://doi.org/10.1007/s00428‐019‐02631‐8
dc.identifier.citedreferenceAl‐Masri H, Ratcliffe M, Sharpe A, et al. Concordance of tumour and immune cell staining with Ventana SP142, Ventana SP263, Dako 22C3 and Dako 28–8 PD‐L1 tests across different cancer types. Virchows Arch. 2017; 471 ( S1 ): 1 ‐ 352. https://doi.org/10.1007/s00428‐017‐2205‐0
dc.identifier.citedreferenceDownes MR, Slodkowska E, Katabi N, Jungbluth AA, Xu B. Inter‐ and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology. 2020; 76: 191 ‐ 200. https://doi.org/10.1111/his.13946
dc.identifier.citedreferenceHodgson A, Slodkowska E, Jungbluth A, et al. PD‐L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am J Surg Pathol. 2018; 42: 1059 ‐ 1066. https://doi.org/10.1097/PAS.0000000000001084
dc.identifier.citedreferenceWang C, Hahn E, Slodkowska E, et al. Reproducibility of PD‐L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. Hum Pathol. 2018; 82: 131 ‐ 139. https://doi.org/10.1016/j.humpath.2018.07.024
dc.identifier.citedreferenceDe Meulenaere A, Vermassen T, Aspeslagh S, et al. Tumor PD‐L1 status and CD8(+) tumor‐infiltrating T cells: markers of improved prognosis in oropharyngeal cancer. Oncotarget. 2017; 8: 80443 ‐ 80452. https://doi.org/10.18632/oncotarget.19045
dc.identifier.citedreferenceDe Meulenaere A, Vermassen T, Creytens D, et al. Importance of choice of materials and methods in PD‐L1 and TIL assessment in oropharyngeal squamous cell carcinoma. Histopathology. 2018; 73: 500 ‐ 509. https://doi.org/10.1111/his.13650
dc.identifier.citedreferenceGatalica Z, Vanderwalde AM, Rose I, et al. Distribution of PD‐L1 expression in diverse cancer types: experience with over 10,000 cases. J Clin Oncol. 2016; 34 ( 15_suppl ): 11548. https://doi.org/10.1200/JCO.2016.34.15_suppl.11548
dc.identifier.citedreferenceKrigsfeld GS, Prince EA, Pratt J, et al. Analysis of real‐world PD‐L1 IHC 28–8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types. J Clin Pathol. 2020; 73: 656 ‐ 664. https://doi.org/10.1136/jclinpath‐2020‐206466
dc.identifier.citedreferenceRatcliffe M, Sharpe A, Rebelatto M, et al. A comparative study of PD‐L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol. 2016; 27: vi328 ‐ vi350. https://doi.org/10.1093/annonc/mdw376.7
dc.identifier.citedreferenceScott M, Wildsmith S, Ratcliffe M, et al. Comparison of patient populations identified by different PD‐L1 assays in head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2018; 29: 375.
dc.identifier.citedreferenceKoppel C, Schwellenbach H, Zielinski D, et al. Optimization and validation of PD‐L1 immunohistochemistry staining protocols using the antibody clone 28‐8 on different staining platforms. Mod Pathol. 2018; 31: 1630 ‐ 1644. https://doi.org/10.1038/s41379‐018‐0071‐1
dc.identifier.citedreferenceEccher A, Fontanini G, Fusco N, et al. Digital slides as an effective tool for programmed death ligand 1 combined positive score assessment and training: Lessons learned from the “Programmed death ligand 1 key learning program in Head‐and‐Neck squamous cell carcinoma”. J Pathol Inform. 2021; 12: 1. https://doi.org/10.4103/jpi.jpi_63_20
dc.identifier.citedreferenceJamshidi P, Kaur A, Liu L, Sullivan M, Watkin W, Paintal A. Inter‐Rater Reliability (IRR) in a Consensus PD‐L1 Immunohistochemistry (IHC) service in an academic multi‐hospital health system. Mod Pathol. 2020; 33 ( suppl 2 ): 1863.
dc.identifier.citedreferenceNielsen A, Manriquez G, Hayden D, et al. Precision and repeatability of the VENTANA PD‐L1 (SP263) assay across six different tumor types. Mod Pathol. 2020; 33 ( suppl 2 ): 830.
dc.identifier.citedreferenceRebelatto MC, Midha A, Mistry A, et al. Development of a programmed cell death ligand‐1 immunohistochemical assay validated for analysis of non‐small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016; 11: 95. https://doi.org/10.1186/s13000‐016‐0545‐8
dc.identifier.citedreferenceMahoney KM, Sun H, Liao X, et al. PD‐L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res. 2015; 3: 1308 ‐ 1315. https://doi.org/10.1158/2326‐6066.CIR‐15‐0116
dc.identifier.citedreferenceInge LJ, Dennis E. Development and applications of computer image analysis algorithms for scoring of PD‐L1 immunohistochemistry. Immuno‐Oncology Technol. 2020; 6: 2 ‐ 8. https://doi.org/10.1016/j.iotech.2020.04.001
dc.identifier.citedreferenceKim H‐N, Jang J, Heo YJ, et al. PD‐L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. Virchows Arch. 2020; 476: 243 ‐ 250. https://doi.org/10.1007/s00428‐019‐02653‐2
dc.identifier.citedreferenceBarnes M, Srinivas C, Bai I, et al. Whole tumor section quantitative image analysis maximizes between‐pathologists’ reproducibility for clinical immunohistochemistry‐based biomarkers. Lab Investig. 2017; 97: 1508 ‐ 1515. https://doi.org/10.1038/labinvest.2017.82
dc.identifier.citedreferenceSung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209 ‐ 249. https://doi.org/10.3322/caac.21660
dc.identifier.citedreferencePulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010; 15: 994 ‐ 1001. https://doi.org/10.1634/theoncologist.2009‐0289
dc.identifier.citedreferenceJohnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020; 6: 92. https://doi.org/10.1038/s41572‐020‐00224‐3
dc.identifier.citedreferenceCohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head‐and‐neck squamous cell carcinoma (KEYNOTE‐040): a randomised, open‐label, phase 3 study. Lancet. 2019; 393: 156 ‐ 167. https://doi.org/10.1016/S0140‐6736(18)31999‐8
dc.identifier.citedreferenceBurtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE‐048): a randomised, open‐label, phase 3 study. Lancet. 2019; 394: 1915 ‐ 1928. https://doi.org/10.1016/S0140‐6736(19)32591‐7
dc.identifier.citedreferenceCanning M, Guo G, Yu M, et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol. 2019; 7: 52. https://doi.org/10.3389/fcell.2019.00052
dc.identifier.citedreferenceFerris RL, Blumenschein GJ, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2‐year long‐term survival update of CheckMate 141 with analyses by tumor PD‐L1 expression. Oral Oncol. 2018; 81: 45 ‐ 51. https://doi.org/10.1016/j.oraloncology.2018.04.008
dc.identifier.citedreferenceHarrington KJ, Ferris RL, Blumenschein G, et al. Nivolumab versus standard, single‐agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health‐related quality‐of‐life results from a randomised, phase 3 trial. Lancet Oncol. 2017; 18: 1104 ‐ 1115. https://doi.org/10.1016/S1470‐2045(17)30421‐7
dc.identifier.citedreferenceFerris RL, Blumenschein GJ, Fayette J, et al. Nivolumab for recurrent squamous‐cell carcinoma of the head and neck. N Engl J Med. 2016; 375: 1856 ‐ 1867. https://doi.org/10.1056/NEJMoa1602252
dc.identifier.citedreferenceFerris RL, Licitra L, Fayette J, et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in checkmate 141 by prior cetuximab use. Clin Cancer Res. 2019; 25: 5221 ‐ 5230. https://doi.org/10.1158/1078‐0432.CCR‐18‐3944
dc.identifier.citedreferenceRies J, Agaimy A, Wehrhan F, et al. Importance of the PD‐1/PD‐L1 axis for malignant transformation and risk assessment of oral leukoplakia. Biomedicines. 2021; 9: 194. https://doi.org/10.3390/biomedicines9020194
dc.identifier.citedreferenceGirolami I, Pantanowitz L, Munari E, et al. Prevalence of PD‐L1 expression in head and neck squamous precancerous lesions: a systematic review and meta‐analysis. Head Neck. 2020; 42: 3018‐3030. Published online June 22, 2020:hed.26339. https://doi.org/10.1002/hed.26339
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jop13220_am.pdf
Size:
473.0KB
Format:
PDF
View/Open
Name:
jop13220.pdf
Size:
677.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.